ABSTRACT PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired antigen-experienced anticancer T cells. However, the efficacy of current PD-L1-blocking antibodies is potentially reduced by 'on-target/off-tumor' binding to PD-L1 widely expressed on normal cells. This lack of tumor selectivity may induce a generalized activation of all antigen-experienced T cells which may explain the frequent occurrence of autoimmune-related adverse events during and after treatment.
Introduction
Immune checkpoint protein programmed death-ligand 1 (PD-L1) normally serves to dampen adoptive immune responses in a timely and localized manner in order to prevent collateral damage and autoimmunity by limiting antigen-experienced PD-1 C / CD8
C T cells to proliferate, produce cytokine and attack cells. 1 However, cancer cells misuse PD-L1 for incapacitating anticancer PD-1 C /CD8 C T cells in the tumor microenvironment. 2 Indeed, PD-L1 expression by cancer cells was found to be associated with unfavorable prognosis in various malignancies. [3] [4] [5] In this process, cancer cells constitutively express PD-L1 due to aberrant oncogenic signaling 6 or upregulate PD-L1 in response to IFN-g locally released by activated anticancer T cells. 2, 7 Blockade of the PD-1/PD-L1 checkpoint using antagonistic antibodies has produced unprecedented antitumor responses in a subgroup of immunogenic cancer types. In particular, PD-L1-blocking antibodies, such as atezolizumab, avelumab, and durvalumab, showed prominent clinical activity in patients with advanced stage melanoma [8] [9] [10] and non-small-cell lung carcinoma (NSCLC). 11, 12 However, the efficacy of current conventional monospecific PD-L1-blocking antibodies is potentially hampered due to on-target/off-tumor binding to numerous normal cell types that also express PD-L1. In this respect, binding to PD-L1-expressing cells in blood or other tissue may prevent antibody extravasation and accumulation at the site of the tumor. 13, 14 Moreover, lack of tumor-selectivity appears to result in generalized activation of antigen-experienced T cells, including functionally silenced autoreactive T cells. The latter aspect is evidenced by the frequent occurrence of severe autoimmune-related adverse events during and after treatment with PD-L1-blocking antibodies.
To address these issues, we developed a bispecific antibody that aims to direct PD-L1-blockade to cancer cells and thereby reactivate anticancer T cells more selectively. Bispecific antibodies (BsAbs) are a valuable class of emerging therapeutics that combine two target functionalities harnessed into one antibody-based molecule. As target for our PD-L1-blocking bsAb we selected the epidermal growth factor receptor (EGFR), a well-established oncogenic tumor-associated surface antigen that is overexpressed and/or mutated in various epithelial malignancies, including colorectal cancer and non-small-cell lung cancer. 15, 16 Of note, FDA-approved anti-EGFR antibodies necitumumab and cetuximab 17 inhibit oncogenic EGFR signaling and show clinical efficacy in cancers also responsive to PD-1/PD-L1 checkpoint inhibition. 18 These notions prompted us to devise a targeted strategy for EGFR-directed blockade of PD-1/PD-L1 interaction. As far as we are aware, this is the first report of a bsAb that selectively directs PD-L1 blockade to EGFR-overexpressing cancer cells. This approach may represent an important step towards enhancing selectivity, efficacy and safety of PD-1/PD-L1 checkpoint inhibition approaches in EGFRoverexpressing malignancies.
Results

PD-L1xEGFR simultaneously binds to PD-L1 and EGFR
PD-L1xEGFR dose-dependently bound to CHO.PD-L1 cells and not to wt CHO cells (Fig. 1A) . Moreover, PD-L1xEGFR dose-dependent bound to A431 cells, whereas PD-L1xMock only showed minimal binding to A431 cells (Fig. 1B) . Binding levels of PD-L1xEGFR towards a panel of PD-L1
C /EGFR C cell lines closely correlated with the respective expression levels of EGFR (Suppl. Fig. 2A ). In contrast, relative low binding of PDL1xEGFR was detected towards a panel of PD-L1
C
/EGFR
¡ cell lines (Fig. 1C) . Further, binding of PD-L1xEGFR to EGFR high A431 cells was strongly inhibited in the presence of excess amounts of EGFR-blocking mAb 425, whereas excess amounts of a PD-L1-blocking mAb only partly inhibited binding. Importantly, binding of PD-L1xEGFR to A431 cells was abrogated only in the combined presence of excess amounts of a PD-L1-blocking mAb and mAb 425 (Fig. 1D) , indicating PDL1xEGFR selectively and simultaneously binds to PD-L1 and EGFR. Since EGFR expression levels on cancer cells typically strongly exceed those of PD-L1, we reason that binding of bsAb PD-L1xEGFR to EGFR C cancer cells is usually dominated by its capacity to target EGFR.
PD-L1xEGFR has superior PD-L1-blocking capacity for PD-L1
C
/EGFR
C cancer cells PD-L1xEGFR and PD-L1xMock were compared for their capacity to block PD-L1 on EGFR-expressing cancer cells using a competitive binding assay. In this assay, the IC50 of PDL1xEGFR for inhibiting the binding of a competing APClabeled PD-L1 mAb to A431 cells was calculated to be 0.013 mg/ml which was »140 times lower than the IC50 calculated for PD-L1xMock. Importantly, when EGFR binding to A431 cells was blocked by pre-incubation with mAb 425, the IC50 of PD-L1xEGFR increased »50 fold (from 0.013 to 0.549 mg/ml; Fig. 1E ). These data indicate that, compared to PD-L1xMock, PD-L1xEGFR has superior PD-L1-blocking capacity for PD-L1 C /EGFR C cancer cells.
PD-L1xEGFR inhibits EGFR-mediated cancer cell proliferation
Treatment with PD-L1xEGFR showed similar capacity as mAb 425 ( Fig. 2A and B ) and cetuximab (data not shown) to inhibit the proliferation of FaDu and H292 cancer cells. In contrast, PD-L1xMock and isotype control antibodies did not impact the proliferation of FaDu or H292 cells.
PD-L1xEGFR blocks PD-1/PD-L1 interaction in an EGFR-directed manner
In the standard PD-1/PD-L1 Blockade Bioassay, PD-L1xEGFR and PD-L1xMock showed comparable dose-dependent blockade of PD-1/PD-L1 interaction with an IC50 value of »2.5 mg/ ml (Fig. 2C ). Of note, in this non-targeted setting the IC50 of MEDI4736 for blocking PD-1/PD-L1 was 18 times lower than that of PD-L1xEGFR and PD-L1xMock. Next, the capacity of PD-L1xEGFR for EGFR-directed PD-1/PD-L1 blockade was assessed by replacing CHO.PD-L1/CD3 cells in the standard PD-1/PD-L1 Blockade Bioassay by A431 cells (PD-L1
) that were pretreated with a suboptimal amount of bsAb BIS-1; an EpCAM-directed CD3-agonistic bsAb. 19 In the presence of BIS-1-coated A431 cells, the luciferase expression by Jurkat.PD1-NFAT-luc cells was effectively repressed. However, treatment with PD-L1xEGFR resulted in a dose-dependent increase in luciferase-mediated luminescence in Jurkat.PD1-NFAT-luc cells (Fig. 2D ). Of note, in this EGFRdirected setting, the capacity of PD-L1xEGFR to release the PD-1/PD-L1 break on luminescence in Jurkat.PD1-NFAT-luc cells became comparable to that of MEDI4736. These results indicate that the PD-L1-blocking activity of PD-L1xEGFR is markedly lower than that of MEDI4736. However, upon concurrent EGFR-binding PD-L1xEGFR regains potent PD-L1-blocking activity comparable to that of MEDI4736.
PD-L1xEGFR enhances activity of bsAb-redirected T cells
Recently, it was reported that blockade of PD-1/PD-L1 augments the killing capacity of BiTE-redirected T cells. 20 In our model system, we used a suboptimal amount of BIS-1 to redirect T cells towards EpCAM C carcinoma cells that was titrated to induce low levels of apoptosis in FaDu and A431 cancer cells. In this setting, addition of PD-L1xEGFR resulted in a potent increase of apoptotic cancer cell death of »35% (Fig. 3A and B) which was accompanied by a markedly increased production of IFN-g (Fig. 3C ) and upregulation of CD25 expression (Suppl. Fig. 2B ). In contrast, addition of MEDI4736 or PD-L1xMock only marginally enhanced (»5%) the cytotoxic potential of BIS-1-redirected T cells. Of note, addition of anti-EGFR mAb 425 appeared to sensitize A431 and FaDu cancer cells to killing by BIS-1-redirected T cells (18% and 22%, respectively), which is likely attributable to its capacity to inhibit oncogenic EGFRsignaling. Addition of PD-L1xEGFR or mAb 425 to T cells that were not redirected by BIS-1 resulted in background levels of apoptosis in FaDu and A431 cells (Fig. 3A and B) . Taken together, this indicates that the capacity of PD-L1xEGFR to enhance the anticancer activity of BIS-1-redirected T cells is attributable to its concurrent ability to block both PD-L1 signaling and oncogenic EGFR-signaling.
Next, we evaluated whether PD-L1xEGFR enhances anticancer activity of BIS-1-redirected T cells in an EGFR-directed manner. To this end, EGFR C and EGFR ¡ cancer cells were briefly incubated with PD-L1xEGFR or control antibodies, after which unbound antibodies were removed by washing. In this setting, PD-L1xEGFR potently enhanced the anticancer activity of BIS-1-redirected T cells towards EGFR C A431 and FaDu cancer cells, with essentially no enhanced activity towards EGFR ¡ A2058.EpCAM cells (Fig. 3D , E, F). In contrast, MEDI4736 only marginally enhanced the anticancer activity of BIS-1-redirected T cells towards cancer cells indiscriminate of EGFR expression. Taken together, PD-L1xEGFR but not MEDI4736 specifically enhances the anticancer activity of BIS-1-redirected T cells in an EGFR-directed manner.
PD-L1xEGFR enhances activity of antigen-experienced T cells
Next, we evaluated the capacity of PD-L1xEGFR to enhance the cytotoxic potential of authentic antigen-experienced T cells. To this end, CMVpp65-experienced T cells from healthy CMVseropositive volunteers were cocultured with A431.pp65 or wt A431 cancer cells. In this setting, PD-L1xEGFR potently enhanced the cytotoxic activity of CMVpp65-experienced T cells towards A431.pp65 and not wt A431 cells. The enhanced cytotoxic potential of these T cells was corroborated by an increased cell surface expression of activation markers CD25, HLA-DR, CD137 and CD107a (Fig. 4A to D and suppl. Fig 3) , and an increased production of IFN-g and granzyme B ( Fig. 4E and F). Of note, expression of CD137 is reported to be restricted to T cells recently activated through TCR-mediated signaling and as such here identified the activation of pp65-experienced anti-CMV CD8 C T cells by PD-L1xEGFR. Similarly, the increased expression of degranulation marker CD107a is indicative of an increased cytotoxic activity of antigen-experienced T cells. 21 Taken together, these results indicated that PD-L1xEGFR enhances the activity of antigenexperienced T cells. In-PD-L1xMock were 15% and 7% ID/g, respectively (Fig 6C and suppl. Fig 4) . In both tumor models the tumor-to-blood-ratio for 111 In-PD-L1xEGFR was notably higher compared to 111 In-PD-L1xMock (p D 0.001) (Fig. 6D ). These data indicate that accumulation of PD-L1xEGFR in EGFR C tumors is higher compared to PD-L1xMock.
PD-L1xEGFR induces NK cell-mediated ADCC in EGFR
Discussion
The efficacy of current PD-L1-blocking antibodies is potentially hampered by 'on-target/off-tumor' binding to normal cells expressing PD-L1. This lack of tumor-selective binding may reduce tumor accretion of PD-1/PD-L1-blocking antibodies. Moreover, this may also induce an indiscriminate reactivation of antigen-experienced T cells, including functionally silenced yet potentially deleterious autoreactive T cells, leading to severe autoimmune-related adverse events during and after treatment. 8, 12, 22 Therefore, we developed a novel bsAb-based approach that aims to more selectively direct PD-L1 blockade to cancer cells. BsAbs allow to selectively target, modulate and interconnect biologic activities of otherwise separately acting cell surface receptors and ligands on the same cell or between neighboring cells in a predesigned manner. of PD-L1xEGFR, PD-L1xMock, MEDI4736 or isotype control. NFAT-RE-mediated luciferase activity was quantified using a plate reader and expressed as fold increase compared to medium control. (D) Similar to C, mixed cultures of A431 cells and Jurkat.PD1-NFAT-luc cells were treated with increasing doses (0.01-10 mg/ml) of indicated antibodies in the presence of 75 ng/ml BIS-1. Statistical analysis in B was performed using One-way ANOVA followed by a Bonferroni post-hoc test ( Ã p < 0.05, ÃÃ p < 0.01, ÃÃÃ p < 0.001, ns not significant).
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We selected EGFR as a particularly suitable target antigen for this approach. Recently, it was reported that EGFR activation by either EGF, exon-19 deletions or L858R mutation promotes PD-L1 expression by cancer cells. 6, 23 EGFR overexpression is known to promote immune evasion of malignant cells by inhibiting the activation of signal transducer and activator of transcription 1 (STAT1) while promoting that of STAT3. 24, 25 Several EGFR-targeted agents are currently available that inhibit oncogenic EGFR signaling, including small-molecule EGFR kinase inhibitors (gefitinib, erlotinib and osimertinib) and antagonistic antibodies (necitumumab, nimotuzumab and cetuximab). Indeed, our results show that gefitinib and erlotinib sensitize cancer cells to apoptosis induction by BIS-1-redirected T cell (Suppl. Fig. 2C  and D) . Moreover, our results suggest that the capacity of PDL1xEGFR to enhance the anticancer activity of BIS-1-redirected T cells is attributable to its concurrent ability to block both PD-L1 signaling and oncogenic EGFR-signaling.
PD-L1xEGFR is constructed in a so-called bispecific taFv-Fc format, 26 a class of symmetric tetravalent bispecific molecules that can be equipped with an Fc domain of choice. Our data demonstrate that the capacity of PD-L1xEGFR to simultaneously bind to PD-L1 and EGFR results in an significantly enhanced overall binding strength (avidity) for PD-L1
C /EGFR C cancer cells. Of note, EGFR expression by carcinoma cells usually exceeds expression of PD-L1. Indeed, in mice with EGFR C xenografts the tumor accumulation of 111 In-PD-L1xEGFR was significantly higher than that of control 111 In-PD-L1xMock. Obviously, more detailed fit-for-purpose evaluation of our approach needs to be performed e.g. in patient-derived xenograft (PDX) models using EGFR-transgenic and humanized NSG mice, but such is clearly beyond the scope of the current report.
Interestingly, in a bioassay for PD-1/PD-L1 blockade PDL1xEGFR showed reduced capacity to block PD-1/PD-L1 compared to PD-L1-blocking antibody MEDI4736. However, upon binding to EGFR-overexpressing target cells the PD-L1-blocking capacity of PD-L1xEGFR was restored to that of MEDI4736. Compared to indiscriminate high-affinity PD-L1-binding activity by MEDI4736, the EGFR-dependent PD-L1-blocking capacity of PD-L1xEGFR may be beneficial to reduce 'on-target/off-tumor' effects.
Our results indicate that PD-L1xEGFR enhances activation of antigen-experienced T cells in an EGFR-directed manner. In particular, treatment of CMV-pp65 transfected EGFR C cancer cells with PD-L1xEGFR, followed by removal of unbound antibody, promoted the activity of HLA-matched CMV-specific CD8 C T cells which was corroborated by increased expression of CD137, CD107a, granzyme B, and IFN-g production. Previously, it was reported that PD-L1-blocking antibody avelumab has similar in vitro capacity to enhance activation of antigenexperienced T cells directed against CMV, EBV, Flu or tetanus, 27 albeit obviously not in a tumor-directed manner. Typically, PD-1/PD-L1-blocking antibodies are engineered as human IgG4 or to have reduced or silenced ADCC activity to avoid elimination of PD-1/PD-L1-expressing immune cells. 28, 29 However, human IgG1 containing avelumab was shown to have a toxicity profile comparable to ADCC-null PD-L1-blocking antibodies [30] [31] [32] with low levels of lysis of PBMCs in vitro. 27, 33 Moreover, NK cell-mediated ADCC by avelumab was shown to enhance its therapeutic functionality. 33, 34 Similarly, the human IgG1 domain present in PD-L1xEGFR may enhance its therapeutic activity as it promotes NK cell-mediated ADCC towards EGFR-expressing cancer cells.
Collectively, our data demonstrates that PD-L1xEGFR has multiple mutually reinforcing anticancer activities not available in any of the current conventional PD-L1-blocking antibodies. In particular, PD-L1xEGFR: 1. simultaneously binds to both PD-L1 and EGFR resulting in enhanced avidity towards PD-L1 C /EGFR C cancer cells; 2. blocks oncogenic EGFR-signaling which sensitizes cancer cells to therapy; 3. blocks PD-1/PD-L1 interaction in an EGFR-directed manner; 4. promotes anticancer activity of both anti-CD3xanti-EpCAM-redirected and antigen-experienced T cells in an EGFR-directed manner; 5. induces elimination of EGFR C tumor cells by NK cell-mediated ADCC; 6. accumulates more selectively in EGFR C xenografts. Taken together, our PD-L1xEGFR-based approach may represent a next step towards enhancing selectivity, efficacy and safety of PD-1/PD-L1 checkpoint inhibition approaches in EGFR-overexpressing malignancies and as such warrants further development.
Materials and methods
Antibodies and reagents
Goat anti-human Ig-PE (Southern Biotech), anti-PD-L1-APC (clone 29E.2A3, BioLegend), anti-EGFR-FITC (clone 528, Santa 
Cell lines and transfectants
Cell lines A431, FaDu, H292, OVCAR3, HT1080, DLD-1, SK-BR-3, LNCaP, A2058, A375 m, A2780, CHO-K1 and Jurkat cells were obtained from the American Type Culture Collection (ATCC). Cells were cultured in RPMI-1640 or DMEM (Lonza), supplemented with 10% fetal calf serum (FCS, Thermo Scientific), CHO-K1 cells were cultured in GMEM (First Link), supplemented with 5% dialyzed FBS (Sigma Aldrich) at 37 C in a humidified 5% CO 2 atmosphere. Cell line authentication was carried out by short tandem repeat (STR) analysis. CHO.PD-L1 cells stably expressing human PD-L1 were generated by lipofection (Fugene-HD, Promega) with plasmid pCMV6-PD-L1 (Origene). A431.pp65 cells stably expressing cytomegalovirus (CMV) protein pp65 were generated by lipofection with plasmid pCMV6-pp65 (Origene). A2058.EpCAM cells stably expressing EpCAM-YFP were generated by lipofection with plasmid pEpCAM-YFP-N1 (kindly provided by Dr. Olivier Gires, Munich, Germany). Clones with stable expression of the indicated transgenes were selected using culture media supplemented with the appropriate antibiotic. PD-L1, EGFR and EpCAM expression was analyzed for all cell lines by flow cytometry using anti-PD-L1-APC, anti-EGFR-FITC and anti-EpCAM-FITC antibodies and appropriate isotype controls. The relative expression levels of PD-L1, EGFR and EpCAM are listed in Supplementary Table 1. In-PD-L1xMock. Tumor uptake was calculated as % injected dose per gram tissue (%ID/g) (D) Tumor-to-blood ratio was calculated, from experiment as described in C. Statistical analysis in D was performed using One-way ANOVA followed by a Bonferroni post-hoc test ( Ã p < 0.05, ÃÃ p < 0.01, ÃÃÃ p < 0.001, ns not significant).
Construction of PD-L1xEGFR
DNA fragments encoding scFvPD-L1 and scFv425 were generated by commercial gene synthesis service (Genscript) based on published VH and VL sequence data of PD-L1-blocking antibody 3G10 and EGFR-directed antibody mAb 425, respectively. For construction and production of PD-L1xEGFR we used eukaryotic expression plasmid pEE14-bsAb, 35 which contains 3 consecutive multiple cloning sites (MCS). MCS#1 and MCS#2 are interspersed by a 22 amino acid flexible linker derived from a CH1 IgG domain. 36 MCS#1, MCS#2 and MCS#3 were used for directional and in-frame insertion of DNA fragments encoding scFvPD-L1, scFv425, and human IgG1 Fc domain, respectively, yielding plasmid pEE14-PD-L1xEGFR (Suppl. Fig. 1A and B) . Of note, pEE14 is equipped with a strong CMV promotor and a murine kappa light-chain leader peptide for driving expression of PD-L1xEGFR through the ER and Golgi complex ensuring excretion of correctly folded and biological active recombinant protein with authentic port-translational modifications. A human IgG1 hinge region and G4S spacers between antigen recognizing domains were applied to promote flexibility of bsAb PD-L1xEGFR (Suppl. Fig. 1C ). Analogously, pEE14-PD-L1xMock encoding PD-L1xMock was constructed by replacing scFv425 in pEE14-PD-L1xEGFR by scFv4-4-20 directed against fluorescein.
Eukaryotic production of bsAbs
PD-L1xEGFR and PD-L1xMock were produced using the Expi293 expression system (ThermoFisher). Briefly, Expi293 cells were transfected with plasmid pEE14-PD-L1xEGFR or pEE14-PD-L1xMock and cultured for 7 days on a shaker platform (125 rpm) at 37 C, 8% CO 2 . Next, culture supernatant was harvested and cleared by centrifugation (3000 x g, 30 min), after which PD-L1xEGFR and PD-L1xMock were purified using an HiTrap protein A HP column connected to an € AKTA Start chromatography system (GE Healthcare Life Sciences).
SDS-PAGE analysis of PD-L1xEGFR
Protein A-purified PD-L1xEGFR or MEDI4736 (2,5 mg) were separated by SDS-PAGE (10% acrylamide) under reducing (with b-mercaptoethanol) or nonreducing conditions (without b-mercaptoethanol), followed by staining of the gel with Coomassie Brilliant Blue. Under nonreducing conditions PDL1xEGFR migrated as a single protein band with an apparent molecular weight of 170 kDa, which dropped to 80 kDa when separated under reducing conditions. This is in good agreement with the calculated molecular weight of 84 kDa for PDL1xEGFR monomer and the proposed disulfide-stabilized dimeric single chain composition of the native protein.
MEDI4736 showed the expected heterodimeric composition of heavy and light chain characteristic for conventional antibodies (Suppl. Fig. 1D ).
Binding activity of PD-L1xEGFR for PD-L1 and EGFR
Flow cytometry was used to evaluate the binding activity of PDL1xEGFR for PD-L1 and EGFR using a broad panel of cell lines (CHO, CHO.PD-L1, EGFR C cancer cell lines A431, FaDu, OVCAR3, HT1080, DLD1, LNCaP and EGFR ¡ cancer cell lines A2058, A375 m, A2780, Jurkat). In short, cells were incubated with increasing amounts of PD-L1xEGFR (0.01-10 mg/ml, 45 min at 4 C), washed 3 times with PBS, and then incubated with anti-human-Ig-PE mAb (45 min at 4 C) and evaluated by flow cytometry. Binding for PD-L1xEGFR (1 mg/ml) to A431 cells was blocked by either PD-L1-blocking mAb (10 mg/ml), mAb 425 (10 mg/ml), or a combination of PD-L1-blocking mAb and mAb 425.
Competitive binding assay
Overall binding strength (avidity) of PD-L1xEGFR and PDL1xMock, for PD-L1
C /EGFR C cancer cells was compared in a competitive binding assay, essentially as described previously. 37 In short, A431 cells were pre-incubated (or not) with excess amounts of mAb 425 (50 mg/ml) for 15 min at 4 C, after which PD-L1xEGFR or PD-L1xMock was added in a concentration range from 0.01 to 50 mg/ml, in the presence of an APC-labeled PD-L1-blocking mAb (8 mg/ml). After 45 min the tumor cellbound APC levels were quantified by flow cytometry. Of note, in this assay, the binding capacity of the tested bispecific antibody is inversely proportional to its capacity to reduce binding of the APC-labeled PD-L1-blocking antibody.
Bioassay for PD-1/PD-L1 blockade
Blockade of PD-1/PD-L1 interaction was assessed using a commercially available PD-1/PD-L1 Blockade Bioassay (Promega). This assay exploits Jurkat.PD1-NFAT-luc T cells (expressing PD-1 and NFAT-inducible luciferase) and CHO-PD-L1-CD3 cells (expressing PD-L1 and a membrane-linked agonistic anti-CD3 antibody). When co-cultured, PD-1/PD-L1 interaction between both cell types inhibits TCR signaling and NFATmediated luciferase activity in Jurkat.PD1-NFAT-luc T cells. Addition of a PD-1/PD-L1 blocking agent, such as PDLxEGFR, PD-L1xMock and MEDI4736, results in releasing PD-1/PD-L1 block on NFAT-mediated luciferase activity in Jurkat.PD1-NFAT-luc T cells.
Bioassay for EGFR-directed PD-1/PD-L1 blockade by PD-L1xEGFR
The capacity of PD-L1xEGFR for EGFR-directed PD-1/PD-L1 blockade was assessed using a modified version of the above PD-1/PD-L1 Blockade Bioassay by replacing CHO.PD-L1/CD3 cells by A431 cells that were pretreated with a suboptimal amount of BIS-1. BIS is an EpCAM-directed CD3-agonistic bsAb. 38 This modification allows for redirecting the Jurkat.
PD1-NFAT-luc T cells towards EpCAM
C A431 carcinoma cells. In short, Jurkat.PD1-NFAT-luc T cells were mixed BIS-1-pretreated A431 cells at a cell ratio of 5 to 1 and then cultured for 18 h in the presence of PD-L1xEGFR or appropriate control antibodies. Subsequently, Bio-Glo reagent was added after which bioluminescence was quantified using a Victor V3 multilabel plate reader (Perkin Elmer).
Inhibition of EGFR-mediated cancer cell proliferation by PD-L1xEGFR
FaDu and H292 cancer cells were pre-cultured in 48-wells plates for 6 h at 8.000 cells/well, followed by addition of PDL1xEGFR, PD-L1xMock or appropriate control antibodies (each 5 mg/ml). After 5 days, cancer cell proliferation was determined in an MTS-based colorimetric assay (CellTiter 96, Promega) using a Victor V3 multi-label plate counter at 490 nm. Absorbance data for maximum cell death were obtained by control treatment with 70% ethanol for 15 min.
Activation BIS-1-redirected T cells by PD-L1xEGFR
T cells were sorted from PBMCs by MACS (human Pan T cell isolation kit, Miltenyi Biotec). T cells were incubated with a suboptimal amount of bsAb BIS-1 (75 ng/ml) and then added to A431, FaDu or A2058.EpCAM target cells in an E:T ratio of 2 to 1, in the presence or absence of PD-L1xEGFR, appropriate control antibodies (each 5 mg/ml), gefitinib, erlotinib (10 nM/ ml) or DMSO control. At day 3, apoptosis induction in cancer cells (Annexin-V) and CD25 expression on T cells were evaluated by flow cytometry.
Activation of CMV-specific T cells by PD-L1xEGFR
A431.CMVpp65 or wild-type (wt) A431 cells were incubated with PD-L1xEGFR or appropriate control antibodies (5 mg/ ml), washed to remove unbound antibody and then cultured in 48-wells plates (3 £ 10 4 cells/well). Freshly isolated PBMCs from a healthy CMV C donor were added to cancer cells at an E:T ratio of 20 to 1. After 4 days, the various experimental conditions were restimulated by adding fresh A431.pp65 or wt A431 cells. At day 7, »50% of PBMCs of the various conditions was used for restimulation with A431.pp65 or wt A431 cancer cells overnight. At day 8, the cytotoxic potential of CMV-specific CD8 C T cells was assessed by measurement of degranulation marker CD107a (FastImmune CD107a APC reagent, BD Pharmingen) and intracellular IFN-g (FIX&-PERM, Nordic-MUbio and anti-IFN-g-PerCP-Cyanine5.5). The remaining 50% of the CD3 C /CD8 C T cells was used for evaluation of cell surface expression of HLA-DR, CD25 and CD137 by flow cytometry. Supernatant was used for granzyme B ELISA.
NK cell-mediated ADCC by PD-L1xEGFR
Natural killer (NK) cells were sorted from PBMCs using the Magnisort TM Negative Selection kit (eBioscience). Sorted NK cells (1 £ 10 6 cells/ml) were stimulated using in RPMI-1640/ FBS medium supplemented with IL-12 (10 ng/ml) for 24 h as described previously. 33 NK cells were washed with PBS and then mixed with cancer cells at the indicated E to T ratios and treated with PD-L1xEGFR, PD-L1xMock or appropriate control antibodies (each 5 mg/ml). After 18 h of treatment, apoptosis was assessed by flow cytometry using Annexin-V staining.
Alternatively, LNCaP cells were co-cultured with PBMCs at an E to T cell ratio of 5 to 1 and then treated with PDL1xEGFR or indicated control antibodies (each 5 mg/ml). After 48 h, ADCC-mediated apoptosis induction in cancer cells was assessed by flow cytometry using Annexin-V staining procedure.
Radiolabeling and in vitro binding of 111 In-PD-L1xEGFR and 111
In-PD-L1xMock
BsAbs PD-L1xEGFR and PD-L1xMock were conjugated with isothiocyanatobenzyl-diethylenetriaminepentaacetic acid (ITC-DTPA, Macro Cyclics) and radiolabeled with 111 In as described previously. 39 To assess binding of radiolabeled bsAbs to PD-L1 and EGFR, A431 and SK-Br-3 cells were incubated for 4 h at 37 C with 21.6 pM 111
In-PD-L1xEGFR or 111 In-PDL1xmock. To show binding specificity for PD-L1 and EGFR, separate wells were incubated with 66 nM non-labeled mAb 425 or MEDI4736. After incubation, cells were lysed using 0.1 M NaOH and cell-associated activity was measured in a shielded well-type gamma counter (Perkin-Elmer, Boston, MA, USA).
Biodistribution in tumor-bearing nude mice
Animal studies were performed using 6-8 weeks old female BALB/c nude mice (Janvier, France) in accordance with the Dutch Act on Animal Experimentation and approved by the institutional Animal Welfare Committee at Radboud University Nijmegen. To determine blood kinetics, two groups of 5 non-tumor bearing mice were injected with 5 mg (0. In-PD-L1xMock (0.2 MBq, n D 5 per group). Three days post injection, mice were euthanized using CO 2 /O 2 -asphyxation. The biodistrubution of radiolabel was determined ex vivo. Tumor, blood, muscle, lung, spleen, pancreas, intestine, kidney, liver, bone, bone marrow and lymph nodes were excised and weighed and evaluated in a gamma counter. To determine the uptake of radiolabeled antibodies in each sample as a fraction of the injected dose, aliquots of the injected dose were counted simultaneously. Results were decay corrected and expressed as percentage injected dose per gram tissue (%ID/g).
Statistical analysis
IC 50 values were determined by nonlinear regression analysis of concentration response curves using GraphPad Prism. Unless otherwise noted, values are mean § SD. Statistical analysis was done by one-way ANOVA followed by Bonferroni post-hoc test, as indicated using Prism software. P<0.05 was defined as a statistically significant difference. 
